1. Home
  2. CDW vs BBIO Comparison

CDW vs BBIO Comparison

Compare CDW & BBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo CDW Corporation

CDW

CDW Corporation

HOLD

Current Price

$118.60

Market Cap

15.2B

ML Signal

HOLD

Logo BridgeBio Pharma Inc.

BBIO

BridgeBio Pharma Inc.

HOLD

Current Price

$69.75

Market Cap

15.3B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CDW
BBIO
Founded
1984
2015
Country
United States
United States
Employees
14800
N/A
Industry
Catalog/Specialty Distribution
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
15.2B
15.3B
IPO Year
2013
2019

Fundamental Metrics

Financial Performance
Metric
CDW
BBIO
Price
$118.60
$69.75
Analyst Decision
Buy
Strong Buy
Analyst Count
8
25
Target Price
$164.88
$83.96
AVG Volume (30 Days)
1.3M
1.8M
Earning Date
05-06-2026
04-28-2026
Dividend Yield
2.08%
N/A
EPS Growth
1.38
N/A
EPS
8.08
N/A
Revenue
$10,768,600,000.00
$502,076,000.00
Revenue This Year
$4.08
$88.16
Revenue Next Year
$4.01
$74.13
P/E Ratio
$14.99
N/A
Revenue Growth
6.32
126.26
52 Week Low
$112.98
$28.33
52 Week High
$189.45
$84.94

Technical Indicators

Market Signals
Indicator
CDW
BBIO
Relative Strength Index (RSI) 41.29 48.95
Support Level $112.98 $61.95
Resistance Level $127.29 $78.83
Average True Range (ATR) 3.36 3.02
MACD 0.56 0.39
Stochastic Oscillator 52.65 24.66

Price Performance

Historical Comparison
CDW
BBIO

About CDW CDW Corporation

CDW Corp is a multi-brand provider of information technology (IT) solutions to businesses, government, education, and healthcare customers in the United States, the United Kingdom, and Canada. The company's offerings range from hardware and software products to integrated IT solutions and services, including on-premise and cloud capabilities across hybrid infrastructure, digital experience, and security. Its reportable segments are Corporate, Small Business, Public, and Other. The Corporate and Small Business segments serve US private sector business customers, while the Public segment consists of government agencies and education and healthcare institutions in the US. The Corporate segment generates the majority of its revenue in the United States.

About BBIO BridgeBio Pharma Inc.

BridgeBio Pharma is a biotechnology company focused on discovering, developing, testing, and delivering transformative treatments for patients with genetic diseases. The company has four programs in its late-stage pipeline focusing on Mendelian disorders, oncology, and gene therapy. One of its key programs, Attruby (acoramidis), is an orally administered small molecule designed to stabilize tetrameric transthyretin for the treatment of transthyretin amyloid cardiomyopathy.

Share on Social Networks: